Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: 2012 Key Findings from Treatment Algorithms: Major Depressive Disorder Highlights the Market Potential for Therapies Approved To Treat MDD Patients

Research and Markets
Posted on: 11 Oct 12

Research and Markets (http://www.researchandmarkets.com/research/6vzrpg/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Major Depressive Disorder" to their offering.

For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI) or selective serotonin and norepinephrine reuptake inhibitor (SNRI) within one year of diagnosis. Most of the drugs in these classes are available as low-cost generics. Our analysis indicates that the patient shares of more recently launched antidepressants, including Pfizer's Pristiq, Sanofi's Aplenzin, and Angelini Labopharm's Oleptro, are much lower than those of generic products in first- and even second-line therapydemonstrating the increasing difficulty that new products are having penetrating the MDD market.

As a result of this environment, marketers of MDD products have turned their attention to the treatment-resistant populationi.e., those patients who fail to respond adequately to first-line SSRIs and SNRIs. This patient population is substantial: More than one-third of MDD patients move to a second-line therapy within the first year of diagnosis, and more than one-half of these patients move to a third-line therapy in the first year, a trend that is consistent with the fact that patients are less likely to respond to a drug after each failed treatment attempt.

These data highlight the market potential for therapies approved to treat MDD patients with an inadequate response to SSRIs and/or SNRIs, such as Bristol-Myers Squibb/Otsuka's atypical antipsychotic Abilify and AstraZeneca's Seroquel XR, as well as emerging therapies targeting treatment-resistant MDD. Indeed, this study finds that adjunctive MDD therapies are steadily gaining patient share.

Key Topics Covered:

1. Background

2. Key Findings for Newly Diagnosed Patients

3. Key Findings for Recently Treated Patients

4. Key Findings by Product

5. Appendix: Methodology

For more information visit http://www.researchandmarkets.com/research/6vzrpg/key_findings_from

Source: Decision Resources, Inc

Business Wire
http://www.businesswire.com/

Last updated on: 11/10/2012

Advertising